Company Overview

XOMA Royalty Corporation is a life sciences royalty and income-focused company that acquires and manages a diversified portfolio of royalty interests and milestone economics tied to biopharmaceutical products. The company operates within the biotechnology and life sciences financial services industries, focusing on non-dilutive monetization of drug development assets rather than conducting internal drug discovery or commercialization. Its primary revenue drivers are royalties, milestone payments, and other contractual income derived from approved therapies and late-stage clinical programs owned or commercialized by third parties.

XOMA’s strategy centers on aggregating long-duration, low-operating-cost royalty streams linked to established or de-risked therapeutic assets, positioning the company as a specialized alternative asset manager within biotechnology. The company traces its origins to XOMA Corporation, founded in 1981 as a monoclonal antibody research company, and underwent a strategic transformation beginning in the late 2010s. This evolution culminated in the rebranding to XOMA Royalty Corporation in 2021, reflecting a full exit from internal R&D and a permanent shift to a royalty-based business model.

Business Operations

XOMA Royalty generates revenue primarily through its Royalty and Income Portfolio, which consists of economic interests in commercial-stage and late-stage biopharmaceutical products. These interests include sales-based royalties, milestone payments tied to regulatory or commercial events, and, in some cases, equity-related consideration. The company does not manufacture, market, or distribute drugs; instead, it relies on counterparties—typically large pharmaceutical or biotechnology companies—for product commercialization and sales execution.

Operations are capital-light and globally oriented, with contractual cash flows linked to products sold in multiple international markets. XOMA Royalty controls a portfolio of royalty assets acquired through direct purchases, structured financings, and legacy transactions from its historical operating business. The company has entered into multiple asset purchase agreements and structured royalty transactions, and it maintains ongoing relationships with pharmaceutical partners commercializing the underlying therapies. Data on specific joint ventures is inconclusive based on available public sources.

Strategic Position & Investments

Strategically, XOMA Royalty positions itself as a consolidator of biopharmaceutical royalty assets, emphasizing portfolio diversification, long-duration cash flows, and exposure to approved or late-stage products. Growth initiatives focus on deploying capital into additional royalty acquisitions, often targeting assets divested by biotechnology companies seeking non-dilutive funding or balance sheet optimization. The company has completed multiple acquisitions of royalty interests since its strategic pivot, including portfolios sourced from corporate divestitures and structured financings.

XOMA Royalty’s investments span multiple therapeutic areas, including immunology, oncology, rare diseases, and endocrinology, depending on the underlying products tied to its royalty interests. The company does not publicly identify all counterparties in detail in every case, and disclosures on certain portfolio assets are aggregated. Where individual asset-level performance data is not disclosed, detailed attribution of revenue to specific products is inconclusive based on available public sources.

Geographic Footprint

The company is headquartered in the United States, with corporate offices located in California. While XOMA Royalty’s internal operations are primarily U.S.-based, its economic exposure is global due to royalty streams tied to products sold across North America, Europe, and parts of Asia-Pacific. This structure allows the company to benefit from international pharmaceutical markets without maintaining foreign operational infrastructure.

XOMA Royalty’s geographic influence is therefore indirect, driven by the global commercialization strategies of its pharmaceutical partners. The company does not report region-by-region operating expenses or headcount outside the United States, and it has no disclosed manufacturing or sales facilities internationally.

Leadership & Governance

XOMA Royalty is led by an executive team with experience in biotechnology finance, corporate strategy, and life sciences transactions. Leadership emphasizes disciplined capital allocation, portfolio diversification, and risk-adjusted returns rather than scientific development. The board and management have articulated a strategic vision centered on building a scalable, sustainable royalty income platform within biotechnology.

Key executives include:

• Owen Hughes – Chief Executive Officer
• Brad Sitko – Chief Financial Officer
• Thomas B. Klein – Chief Operating Officer
• John Varian – Chairman of the Board

The company’s governance framework reflects its evolution from an operating biotech to a financial royalty company, with executive incentives and oversight aligned toward long-term cash flow generation and shareholder value. Where historical founder attribution is concerned, XOMA Royalty itself does not have a distinct founder separate from XOMA Corporation, and founder-specific data is inconclusive based on available public sources.